How i treat essential thrombocythemia

Research output: Contribution to journalReview article

Abstract

Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm that may be complicated by vascular events, including both thrombosis and bleeding. This disorder may also transform into more aggressive myeloid neoplasms, in particular into myelofibrosis. The identification of somatic mutations of JAK2, CALR, or MPL, found in about 90% of patients, has considerably improved the diagnostic approach to this disorder. Genomic profiling also holds the potential to improve prognostication and, more generally, clinical decision-making because the different driver mutations are associated with distinct clinical features. Prevention of vascular events has been so far the main objective of therapy, and continues to be extremely important in the management of patients with ET. Lowdose aspirin and cytoreductive drugs can be administered to this purpose, with cytoreductive treatment being primarily given to patients at high risk of vascular complications. Currently used cytoreductive drugs include hydroxyurea, mainly used in older patients, and interferon a, primarily given to younger patients. There is a need for disease-modifying drugs that can eradicate clonal hematopoiesis and/ or prevent progression to more aggressive myeloid neoplasms, especially in younger patients. In this article, we use a case-based discussion format to illustrate our approach to diagnosis and treatment of ET.

Original languageEnglish
Pages (from-to)2403-2414
Number of pages12
JournalBlood
Volume128
Issue number20
DOIs
Publication statusPublished - Nov 17 2016

Fingerprint

Essential Thrombocythemia
Pharmaceutical Preparations
Blood Vessels
Hydroxyurea
Interferons
Aspirin
Decision making
Neoplasms
Primary Myelofibrosis
Mutation
Hematopoiesis
Thrombosis
Therapeutics
Hemorrhage

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

How i treat essential thrombocythemia. / Rumi, Elisa; Cazzola, Mario.

In: Blood, Vol. 128, No. 20, 17.11.2016, p. 2403-2414.

Research output: Contribution to journalReview article

Rumi, Elisa ; Cazzola, Mario. / How i treat essential thrombocythemia. In: Blood. 2016 ; Vol. 128, No. 20. pp. 2403-2414.
@article{f52b8df4969145e4903ba88a05eed4ca,
title = "How i treat essential thrombocythemia",
abstract = "Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm that may be complicated by vascular events, including both thrombosis and bleeding. This disorder may also transform into more aggressive myeloid neoplasms, in particular into myelofibrosis. The identification of somatic mutations of JAK2, CALR, or MPL, found in about 90{\%} of patients, has considerably improved the diagnostic approach to this disorder. Genomic profiling also holds the potential to improve prognostication and, more generally, clinical decision-making because the different driver mutations are associated with distinct clinical features. Prevention of vascular events has been so far the main objective of therapy, and continues to be extremely important in the management of patients with ET. Lowdose aspirin and cytoreductive drugs can be administered to this purpose, with cytoreductive treatment being primarily given to patients at high risk of vascular complications. Currently used cytoreductive drugs include hydroxyurea, mainly used in older patients, and interferon a, primarily given to younger patients. There is a need for disease-modifying drugs that can eradicate clonal hematopoiesis and/ or prevent progression to more aggressive myeloid neoplasms, especially in younger patients. In this article, we use a case-based discussion format to illustrate our approach to diagnosis and treatment of ET.",
author = "Elisa Rumi and Mario Cazzola",
year = "2016",
month = "11",
day = "17",
doi = "10.1182/blood-2016-05-643346",
language = "English",
volume = "128",
pages = "2403--2414",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - How i treat essential thrombocythemia

AU - Rumi, Elisa

AU - Cazzola, Mario

PY - 2016/11/17

Y1 - 2016/11/17

N2 - Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm that may be complicated by vascular events, including both thrombosis and bleeding. This disorder may also transform into more aggressive myeloid neoplasms, in particular into myelofibrosis. The identification of somatic mutations of JAK2, CALR, or MPL, found in about 90% of patients, has considerably improved the diagnostic approach to this disorder. Genomic profiling also holds the potential to improve prognostication and, more generally, clinical decision-making because the different driver mutations are associated with distinct clinical features. Prevention of vascular events has been so far the main objective of therapy, and continues to be extremely important in the management of patients with ET. Lowdose aspirin and cytoreductive drugs can be administered to this purpose, with cytoreductive treatment being primarily given to patients at high risk of vascular complications. Currently used cytoreductive drugs include hydroxyurea, mainly used in older patients, and interferon a, primarily given to younger patients. There is a need for disease-modifying drugs that can eradicate clonal hematopoiesis and/ or prevent progression to more aggressive myeloid neoplasms, especially in younger patients. In this article, we use a case-based discussion format to illustrate our approach to diagnosis and treatment of ET.

AB - Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm that may be complicated by vascular events, including both thrombosis and bleeding. This disorder may also transform into more aggressive myeloid neoplasms, in particular into myelofibrosis. The identification of somatic mutations of JAK2, CALR, or MPL, found in about 90% of patients, has considerably improved the diagnostic approach to this disorder. Genomic profiling also holds the potential to improve prognostication and, more generally, clinical decision-making because the different driver mutations are associated with distinct clinical features. Prevention of vascular events has been so far the main objective of therapy, and continues to be extremely important in the management of patients with ET. Lowdose aspirin and cytoreductive drugs can be administered to this purpose, with cytoreductive treatment being primarily given to patients at high risk of vascular complications. Currently used cytoreductive drugs include hydroxyurea, mainly used in older patients, and interferon a, primarily given to younger patients. There is a need for disease-modifying drugs that can eradicate clonal hematopoiesis and/ or prevent progression to more aggressive myeloid neoplasms, especially in younger patients. In this article, we use a case-based discussion format to illustrate our approach to diagnosis and treatment of ET.

UR - http://www.scopus.com/inward/record.url?scp=85015432523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015432523&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-05-643346

DO - 10.1182/blood-2016-05-643346

M3 - Review article

C2 - 27561316

AN - SCOPUS:85015432523

VL - 128

SP - 2403

EP - 2414

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -